[ad_1]
Nemes Laszlo/iStock via Getty Images
OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention of recurrent, fully resected, lung metastatic osteosarcoma.
Results indicated that the candidate met its primary endpoint of 12-month event-free survival. OST-HER2 had
[ad_2]
[ad_1] code6d/E+ via Getty Images The U.S. 10-year Treasury (US10Y) at 4.7% is weighing on equities’ prices, but it is providing an increasingly attractive return, said Christopher P. Harvey, head of Equity Strategy at Wells Fargo. He highlighted that IG credit spreads, which are now up [ad_2]
[ad_1] CleanSpark surpasses over 10,000 bitcoins in treasury [ad_2]
[ad_1] Discipline Fund ETF declares quarterly distribution of $0.2574 [ad_2]
[ad_1] Cintas purchase of US Steel would be accretive – analyst [ad_2]
[ad_1] Global X Blockchain ETF declares semi-annual distribution of $3.7553 [ad_2]
[ad_1] MtronPTI awarded over $10M production contract for a U.S. Defense Program [ad_2]